Phase 2 N=8 Glutamatergic Modulation of Cocaine-related Deficits
Cocaine Dependence
Primary: Change in Cue Reactivity — 126; 18; 16 units on a scale (0-200), high is worse
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer
Gastric Cancer
Primary: Percentage of Participants With Day 43 Serum Pertuzumab Trough Concentrations (Cmin) Greater Than or Equal to (>=) 20 Microgram Per Milliliter (mcg/mL) — 91.6; 98.3…
Phase 2 N=61 A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer
Non-small Cell Lung Cancer
Primary: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) Objective Tumor Response Rate (ORR) — 48.1…
Phase 2 N=14 A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration
Wet Macular Degeneration
Primary: Change From Baseline in CRT as Measured by SD-OCT on Day 29 — 44.0 μm
Phase 2 N=25 Effect of Simethicone on Eustachian Tube Dysfunction
Otitis Media
Primary: Fraction of Middle Ear (ME) Pressure Equilibrated (FGE) — 0.17; 0.24; 0.19; 0.23 ratio — p==0.93
Phase 2 N=55 Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q) · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Rate of Complete Remission — 25 patients
Phase 2 N=6 A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
Ovarian Sarcoma · Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma
Primary: Efficacy (as Measured by Objective Response Rate) of Akt Inhibitor MK2206 in Patients With Recurrent High-grade Platinum-resistant Serous Ovarian, Fallopian Tube, or…
Phase 2 N=63 A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Grades 3/4, and Death — 26; 10; 21; 3 participants
Phase 2 N=10 A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.
Myelodysplastic Syndromes
Primary: Percentage of Participants With Clinical Response as Measured by the International Working Group (IWG) Criteria for Hematological Improvement — 50.00; 71.43; 100.00…
Phase 2 N=46 Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB)
Metastatic Pancreatic Cancer
Primary: To Determine Response Rate to the GTX Regimen in Patients With Pancreatic Cancer
Phase 2 N=41 Capecitabine and Temozolomide for Neuroendocrine Cancers
Neuroendocrine Tumors
Primary: Number of Participants With Partial Response (PR) — 9 participants
Phase 2 N=37 A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer
Pancreatic Cancer
Primary: Number of Subjects Who Experience Dose Limiting Toxicities (DLTs)
Phase 2 N=32 Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar
Pancreatic Cancer Stage IVA
Primary: Conversion Rate of Inoperable to Operable
Phase 2 N=70 Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Primary: Response Rate (RR) After 6 Cycles of Therapy Using the Proposed International Myeloma Working Group Uniform Response Criteria — 86.7; 71.4 percentage of participants
Phase 2 N=109 A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
Breast Cancer
Primary: Median Time to Disease Progression — 171; 171 Days